Is LexaGene a good investment?
/LexaGene is revolutionizing microbial contamination control with its cutting-edge MiQLab® system, delivering swift and on-site pathogen detection. This groundbreaking technology is poised to disrupt multi-billion-dollar markets, including biopharmaceutical development, veterinary diagnostics, food safety testing, and other open-access sectors that demand rapid, precise answers. The best part? You can invest in Lexagene today.
With LexaGene's MiQLab® system, the time required for pathogen detection is slashed to just around 2 hours, a remarkable advancement compared to the reference lab's what could be a lengthy 5-6 day or more turnaround. This accelerated detection not only enhances manufacturing efficiencies for the biopharma manufacturers but also translates into significant cost savings for them.
Notably, LexaGene first generation technology has already generated revenue and has established relationships with major biopharmaceutical giants, and continues to enhance and improve the technology.
Today, LexaGene invites the everyday investor to join in its journey toward success. But, is investing in LexaGene worth the risk? Keep reading and decide for yourself.
Should you invest in LexaGene?
LexaGene is a pioneering molecular diagnostics company on a mission to revolutionize pathogen detection. Its core innovation is a fully automated, rapid pathogen detection system designed for point-of-need use, right where samples are collected. This breakthrough technology offers unmatched ease-of-use, sensitivity, and a broad spectrum of pathogen detection capabilities.
The company’s flagship product, the MiQLab® system, is set to transform pathogen detection across multi-billion-dollar markets, including biopharmaceutical production and development, veterinary diagnostics, food safety testing, and various open-access sectors that demand swift and precise answers.
LexaGene’s vision extends beyond the development of cutting-edge technology to encompass redefining the landscape of pathogen detection and identification, catalyzing research and bolstering prevention through the widespread adoption of open-access technology.
The ultimate goal is to provide fully automated, rapid molecular testing at the point-of-need, ensuring accurate detection and characterization of pathogens. Moreover, the company’s efforts are poised to eventually exert a positive influence on the responsible use of antibiotics, countering their widespread over-prescription in both veterinary care and human healthcare.
The LexaGene stock is capturing the attention of investors
Biopharmaceutical manufacturers face a critical challenge: the speed of receiving test results can significantly impact their operations. In veterinary settings, where diagnosing bacterial or viral infections in animals can take days, expediting results can revolutionize diagnoses. Faster results empower treating veterinarians with precise data, enabling them to make more targeted antibiotic and treatment decisions.
Moreover, manufacturers run the risk of incurring substantial financial losses due to contamination during the biopharmaceutical manufacturing process. Biologics, such as vaccines, monoclonal antibodies, and recombinant proteins, are produced in nutrient-rich bio-reactors, making them susceptible to contamination. This potential contamination can lead to substantial financial setbacks.
Regulatory oversight from the Food and Drug Administration (FDA) is stringent, with zero tolerance for contaminated products. The FDA prohibits the sale of any final product with detectable Mycoplasma contamination. Shockingly, 15% to 80% of U.S. laboratory cell cultures are contaminated with Mycoplasma, and it can take a lengthy 28 days to confirm its absence. The cost of contamination events is exorbitant, affecting product shelf-life. Larger bioreactors carry a heightened contamination risk, making early detection paramount. Detecting contaminants early can prevent losses of less than $0.5 million, whereas late detection can result in financial impacts exceeding $20 to $100 million.
LexaGene's MiQLab provides a game-changing solution by enabling point-of-manufacturing testing during biopharmaceutical development, effectively mitigating financial risk. Currently, the FDA mandates contamination testing only at the end of the production line, creating potential financial jeopardy for manufacturers. Notably, LexaGene's testing system has received feasibility confirmation from pharmaceutical companies with billions of dollars in collective revenues.
While existing testing protocols can detect and limit contamination risks, LexaGene's technology offers the added advantage of more frequent testing with remarkably shorter time-to-results, approximately two hours. This innovative testing technology holds the potential for broader applications in human settings, subject to LexaGene's successful completion of the FDA clearance process.
LexaGene’s plans for growth
The strategic vision for LexaGene centers on the production and provision of MiQLab systems to serve both the biopharmaceutical and veterinary markets. To achieve this, they are seeking additional funding to fully commercialize this technology and complete validation initially in the biopharmaceutical market, a process estimated to span 18 to 24 months. This next-generation MiQLab will not only enhance capabilities but significantly accelerate processes.
Furthermore, the company foresees the potential expansion of our technology into veterinary diagnostics, food testing and human diagnostic testing following successful FDA approval.
The total addressable biopharmaceutical testing market is estimated at $15 to $20 billion. LexaGene’s aim is to capture a modest 2% to 3% market penetration, which could translate into an impressive annual revenue range of approximately $300 million to $500 million.
Similarly, within the veterinary diagnostics sector, which comprises 32,000 veterinary hospitals and clinics, the market is projected to reach $16.9 billion by 2030. A 2% to 3% market penetration here could yield annual revenues ranging from $300 million to $500 million.
Is LexaGene a good investment?
If you’re wondering, “should I invest in LexaGene?” and should you buy LexaGene stock, at Money & Mimosas we encourage you to ask yourself three questions:
What are the potential roadblocks?
What is the potential growth or upside?
How does this align with my values and/or overall investment strategy?
One of the primary challenges facing LexaGene is the competitive landscape. In the veterinary diagnostic sector, established players such as IDEXX, Antech, and Zoetis, present a formidable competitive presence. However, it's crucial to note that these same entities could ultimately become “partners” with LexaGene in the further development of the technology in the veterinary sector.
Despite this competitive environment, we see immense potential for LexaGene, starting with the exceptional leadership team. The company is led by a talented and experienced management team with a proven track record of success in the molecular diagnostics industry. Dr. Jack Regan, the inventor of LexaGene's patented microfluidic system, is a notable figure on the team.
He previously played a pivotal role as the lead scientist in developing a predecessor instrument designed for bio-warfare surveillance. This instrument was adopted by the Department of Homeland Security for the BioWatch Program. Dr. Regan also contributed to the development of a second R&D instrument tailored for detecting respiratory pathogens from nasal swab samples, with the development of these instruments supported by $20 million in government funding.
LexaGene's commitment to innovation is underscored by the substantial earlier investment of approximately $40 million in the development of this groundbreaking technology. The patented technology behind the MiQLab® System has the potential to revolutionize the molecular diagnostics industry. Despite the competitive landscape, LexaGene shows promise in its ability to offer unmatched speed and precision in pathogen detection, backed by a strong leadership team.
Keep reading to learn more about the LexaGene stock price and how to buy LexaGene stock.
How to buy LexaGene stock
You can invest in LexaGene for $1.03 per share. The minimum investment is $1030 and is open to all investors. You don’t have to be an accredited investor to invest in LexaGene.
The process of investing is really easy. You head over to the investment page and click the ‘Invest Now’ button. From there, the website will walk you through the seamless process of becoming an investor with LexaGene.
